Bexsero Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

bexsero

gsk vaccines s.r.l. - ytri himnu frá neisseria meningitidis hópur b (álag nýja-sjáland 98/254), skal læknir hafa neisseria meningitidis hópur b fhbp samruna prótín, skal læknir hafa neisseria meningitidis hópur b nada prótín, skal læknir hafa neisseria meningitidis hópur b nhba samruna prótín - meningitis, meningococcal - meningókokka bóluefni - virkt ónæmisaðgerðir gegn innrásarsjúkdómum af völdum neisseria meningitidis serogroup-b stofnanna.

NeisVac-C Stungulyf, dreifa Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

neisvac-c stungulyf, dreifa

pfizer aps - neisseria meningitidis c (oligosakkaríð eða polýsakkaríð) - stungulyf, dreifa

Mircera Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

mircera

roche registration gmbh - metoxý annara hættu efst-epóetín beta - anemia; kidney failure, chronic - sýklalyf - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5. treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.